Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Tenaya Therapeutics Inc TNYA

Healthcare Biotechnology
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s... see more

Recent & Breaking News (NDAQ:TNYA)

Tenaya Therapeutics Reports Promising Early Data from MyPEAK(TM)-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

GlobeNewswire 9 days ago

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

GlobeNewswire 9 days ago

Tenaya Therapeutics Doses First Patient in RIDGE(TM)-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

GlobeNewswire November 25, 2024

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire November 19, 2024

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 6, 2024

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

GlobeNewswire October 17, 2024

Tenaya Therapeutics to Participate in Upcoming Investment Conferences

GlobeNewswire September 3, 2024

Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 8, 2024

Tenaya Therapeutics Announces Research Leadership Updates

GlobeNewswire June 27, 2024

Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

GlobeNewswire June 18, 2024

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 14, 2024

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

GlobeNewswire May 2, 2024

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 18, 2024

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

GlobeNewswire March 18, 2024

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire February 27, 2024

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

GlobeNewswire February 26, 2024

Tenaya Therapeutics Announces Pricing of Underwritten Offering

GlobeNewswire February 8, 2024

Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

GlobeNewswire November 21, 2023

Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 8, 2023